血清MicroRNA作为生物学标记物对肝硬化诊断及预后判断研究进展

doi:10.3969/j.issn.1672-5069.2016.05.033

Abstract

Ma Shulin, Liu Xiaofeng.. Serum MicroRNA in diagonsis of patients with liver cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(5): 629-632.

[1] Wang FS,Fan JG,Zhang Z,et al. The global burden of liver disease:the major impact of China. Hepatology,2014,60（6）:2099-2108.
[2] Gui J,Tian Y,Wen X,et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci,2011,12（1）:183-193.
[3] Farina NH,Wood ME,Perrapato SD,et al. Standardizing analysis of circulating microRNA:clinical and biological relevance. J Cell Biochem,2014,115（5）:805-811.
[4] Ziol M,Handra-Luca A,Kettaneh A,et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology,2005,41（1）:48-54.
[5] Roderburg C,Mollnow T,Bongaerts B,et al. Micro-RNA profiling in human serum reveals compartment-specific roles of miR-571 and miR-652 in liver cirrhosis. PloS One,2012,7（3）:e32999.
[6] Zhao G,Zhang ZQ,Zhang B,et al. Down-regulation of tTG expression by RNAi inhibits HSC proliferation and attenuates liver fibrosis. Int J Clin Exp Pathol,2011,4（5）:513-520.
[7] Marquez RT,Wendlandt E,Galle CS,et al. MicroRNA-21 is upregulated during the proliferative phase of liver regeneration, targets Pellino-1,and inhibits NF-κB signaling.Am J Physiol Gastrointest Liver Physiol,2010,298（4）:G535-G541.
[8] Chen G,Wang Y,Li M,et al. Curcumol induces HSC-T6 cell death through suppression of Bcl-2:involvement of PI3K and NF-kappaB pathways. Eur J Pharm Sci,2014,6（5）:21-28.
[9] Zhang DS,Li YY,Chen XJ,et al. BCL2 promotor methylation and miR-15a/16-1 upregulation is associated with sanguinarine-induced apoptotic death in rat HSC-T6 cells. J Pharmacol Sci,2015,127（1）:135-144.
[10] Wang J,Eagle SH,Chu Y,et al. microRNA-29b prevents liver fibrosis by attenuating hepatic stellate cell activation and inducing apoptosis through targeting PI3KAKT pathway. Oncotarget,2014,pii: 2621.（[Epub ahead of print].
[11] Arroyo JD,Chevillet JR,Kroh EM,et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A,2011,108（12）:5003-5008.
[12] Chen X,Ba Y,Ma L,et al. Characterization of microRNAs in serum:a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res,2008,18（10）:997-1006.
[13] Laterza OF,Lim L,Garrett-Engele PW,et al. Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem,2009,55（11）:1977-1983.
[14] Mundalil Vasu M,Anitha A,Thanseem I,et al. Serum microRNA profiles in children with autism. Mol Autism,2014,5（6）:40.
[15] Mitchell PS,Parkin RK,Kroh EM,et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A,2008,105（30）:10513-10518.
[16] Bianchi F,Nicassio F,Marzi M,et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med,2011,3（8）:495-503.
[17] Farid WR,Pan Q,van der Meer AJ, et al. Hepatocyte-derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation. Liver Transpl,2012,18（3）:290-297.
[18] Bala S,Petrasek J,Mundkur S,et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic,drug-induced,and inflammatory liver diseases. Hepatology,2012,56（5）:1946-1957.
[19] Creemers EE,Tijsen AJPinto YM,et al. Circulating microRNAs novel biomarkers and extracellular communicators in cardiovascular disease Circ Res,2012,110（3）:483-495.
[20] Farid WR,Verhoeven CJ,Jonge J,et al. The ins and outs of microRNAs as biomarkers in liver disease and transplantation. Transplant Int,2014,27（12）:1222-1232.
[21] Cortez MA,Bueso-Ramos C,Ferdin J,et al. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol,2011,8（8）:467-477.
[22] Starkey Lewis PJ,Dear J,Platt V,et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology,2011,54（5）:1767-1776.
[23] Xu J,Wu C,Che X,et al. Circulating MicroRNAs,miR-21,miR-122,and miR-223,in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog,2011,50（2）:136-142.
[24] Zhang Y,Jia Y,Zheng R,et al. Plasma microRNA-122 as a biomarker for viral-,alcohol-,and chemical-related hepatic diseases. Clin Chem,2010,56（12）:1830-1838.
[25] Li LM,Hu ZB,Zhou ZX,et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res,2010,70（23）:9798-9807.
[26] Yan JW,Lin J,She XX, et al. The emerging role of miR-375 in cancer. Int J Cancer,2014,135（5）:1011-1018.
[27] Hou J,Lin L,Zhou W,et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer cell,2011,19（2）:232-243.
[28] Wei X,Xiang T,Ren G,et al. miR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A. Cell signal,2013,25（2）:439-446.
[29] Xie Y,Yao Q,Butt AM,et al. Expression profiling of serum microRNA-101 in HBV-associated chronic hepatitis,liver cirrhosis,and hepatocellular carcinoma. Cancer Biol Ther,2014,15（9）:1248-1255.
[30] He Y,Huang C,Sun X,et al. MicroRNA-146a modulates TGF-beta1-induced hepatic stellate cell proliferation by targeting SMAD4. Cell Signal,2012,24（10）:1923-1930.
[31] El Ouaamari A,Baroukh N,Martens GA,et al. miR-375 targets 3'-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells. Diabetes,2008,57（10）:2708-2717.
[32] Ogawa T,Iizuka M,Sekiya Y,et al. Suppression of type I collagen production by microRNA-29b in cultured human stellate cells.Biochem Biophys Res Commun,2010,391（1）:316-321.
[33] Chen YJ,Zhu JM,Wu H,et al. Circulating microRNAs as a fingerprint for liver cirrhosis. PloS One,2013,8（6）:e66577.
[34] Wang B,Li W,Guo K,et al. miR-181b promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. Biochem Biophys Res Commun,2012,421（1）:4-8.
[35] Trebicka J,Anadol E,Elfimova N,et al. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol,2013,58（2）:234-239.
[36] Waidmann O,Koberle V,Brunner F,et al. Serum microRNA-122 predicts survival in patients with liver cirrhosis. PloS One,2012,7（9）:e45652.
[37] Wu H,Wang F,Hu S,et al. MiR-20a and miR-106b negatively regulate autophagy induced by leucine deprivation via suppression of ULK1 expression in C2C12 myoblasts. Cell signal,2012,24（11）:2179-2186.
[38] Huang CF,Sun CC,Zhao F,et al. miR-33a levels in hepatic and serum after chronic HBV-induced fibrosis. J Gastroenterol,2014,12（8）:20-25.
[39] Roderburg C,Urban GW,Bettermann K,et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology,2011,53（1）:209-218.\
[40] Roderburg CLuedde T. Circulating microRNAs as markers of liver inflammation, fibrosis and cancer.J Hepatol,2014,61（6）:1434-1437.
[41] Wojcicka A,Swierniak M,Kornasiewicz O,et al. Next generation sequencing reveals microRNA isoforms in liver cirrhosis and hepatocellular carcinoma.Int J Biochem Cell Biol,2014,53（9）:208-217.

Serum MicroRNA in diagonsis of patients with liver cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[3]	. Consensus on the diagnosis and therapy of hepatic fibrosis [J]. Journal of Practical Hepatology, 2019, 22(6): 793-803.
[4]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[5]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[6]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[7]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[8]	Zeng Yanni, Zhang Can, Bi Junying, et al.. Value of long-time delayed enhancement scan of MRI in the diagnosis of solitary necrotic nodule of liver [J]. Journal of Practical Hepatology, 2019, 22(6): 900-903.
[9]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[10]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[11]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[12]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[13]	Wang Yueyuan, Wang Yan, Zhang Dandan. Short-term efficacy of terlipressin and octreotide combination in treatment of cirrhotic patients complicated by hepatorenal syndrome [J]. Journal of Practical Hepatology, 2019, 22(5): 684-687.
[14]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[15]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.